Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Twist Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TWST's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: TWST exceeded the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: TWST exceeded the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Twist Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StShareholders Are Raving About How The Twist Bioscience (NASDAQ:TWST) Share Price Increased 304%
1 month ago | Simply Wall StDon't Ignore The Fact That This Insider Just Sold Some Shares In Twist Bioscience Corporation (NASDAQ:TWST)
2 months ago | Simply Wall StIs Twist Bioscience (NASDAQ:TWST) A Risky Investment?
Is Twist Bioscience undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TWST's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TWST's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TWST is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TWST is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TWST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TWST is overvalued based on its PB Ratio (11.1x) compared to the US Biotechs industry average (3.3x).
How is Twist Bioscience forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TWST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TWST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TWST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TWST's revenue (37.9% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: TWST's revenue (37.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TWST is forecast to be unprofitable in 3 years.
How has Twist Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TWST is currently unprofitable.
Growing Profit Margin: TWST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TWST is unprofitable, and losses have increased over the past 5 years at a rate of 31.5% per year.
Accelerating Growth: Unable to compare TWST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TWST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: TWST has a negative Return on Equity (-42.07%), as it is currently unprofitable.
How is Twist Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: TWST's short term assets ($344.6M) exceed its short term liabilities ($31.4M).
Long Term Liabilities: TWST's short term assets ($344.6M) exceed its long term liabilities ($27.9M).
Debt to Equity History and Analysis
Debt Level: TWST's debt to equity ratio (1.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if TWST's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TWST has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TWST has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 31.4% each year
What is Twist Bioscience current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TWST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TWST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TWST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TWST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TWST's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Emily Leproust (46 yo)
Dr. Emily Marine Leproust, Ph.D., serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She co-founded Twist Bioscience Corporation in 2013 and has been its Chief Executive Offi ...
CEO Compensation Analysis
Compensation vs Market: Emily's total compensation ($USD8.13M) is above average for companies of similar size in the US market ($USD5.63M).
Compensation vs Earnings: Emily's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||2.5yrs||US$3.05m||0.020% |
|Chief Commercial Officer||1.75yrs||US$3.01m||0.0092% |
|Chief Operating Officer||0.75yr||no data||0.030% |
|Senior VP||4.17yrs||US$703.97k||0.062% |
|Vice President of Human Resources||4.58yrs||no data||0.014% |
|Senior VP of Advanced Development||7.5yrs||no data||1.03% |
|Chief Scientific Officer of BioPharma & VP of Protein Engineering||2.33yrs||no data||no data|
|Senior Vice President of Operations||1.67yrs||no data||no data|
|Senior Vice President of Government Affairs & Public Policy||0.33yr||no data||no data|
Experienced Management: TWST's management team is considered experienced (2 years average tenure).
|Senior VP of Advanced Development||7.5yrs||no data||1.03% |
|Independent Director||7yrs||US$89.75k||0% |
|Lead Independent Director||2yrs||US$89.75k||0.0068% |
|Independent Director||1.42yrs||US$217.77k||0.0065% |
|Independent Director||3.92yrs||US$89.75k||3.97% |
|Independent Non-Employee Director||1yr||no data||no data|
|Independent Director||2yrs||US$429.74k||0% |
|Independent Director||2.25yrs||no data||no data|
Experienced Board: TWST's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TWST insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.5%.
Twist Bioscience Corporation's company bio, employee growth, exchange listings and data sources
- Name: Twist Bioscience Corporation
- Ticker: TWST
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.888b
- Shares outstanding: 44.66m
- Website: https://www.twistbioscience.com
Number of Employees
- Twist Bioscience Corporation
- 681 Gateway Boulevard
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TWST||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2018|
|0ME||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2018|
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DN ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/22 23:45|
|End of Day Share Price||2020/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.